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ABSTRACT
Introduction: In the 2-year CARE-MS trials
(NCT00530348; NCT00548405) in patients with
relapsing–remitting multiple sclerosis, alem-
tuzumab showed superior efficacy versus sub-
cutaneous interferon beta-1a. Efficacy was
maintained in two consecutive extensions
(NCT00930553; NCT02255656). This post hoc
analysis compared disability outcomes over
9 years among alemtuzumab-treated patients
according to whether they experienced con-
firmed disability improvement (CDI) or wors-
ening (CDW) or neither CDI nor CDW.
Methods: CARE-MS patients were randomized
to receive two alemtuzumab courses
(12 mg/day; 5 days at baseline; 3 days at
12 months), with additional as-needed 3-day
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courses in the extensions. CDI or CDW were
defined as C 1.0-point decrease or increase,
respectively, in Expanded Disability Status Scale
(EDSS) score from core study baseline confirmed
over 6 months, assessed in patients with base-
line EDSS score C 2.0. Improved or stable EDSS
scores were defined as C 1-point decrease or
B 0.5-point change (either direction), respec-
tively, from core study baseline. Functional
systems (FS) scores were also assessed.
Results: Of 511 eligible patients, 43% experi-
enced CDI and 34% experienced CDW at any
time through year 9 (patients experiencing both
CDI and CDW were counted in each individual
group); 29% experienced neither CDI nor CDW.
At year 9, patients with CDI had a -0.58-point
mean EDSS score change from baseline; 88%
had stable or improved EDSS scores. Improve-
ments occurred across all FS, primarily in sen-
sory, pyramidal, and cerebellar domains.
Patients with CDW had a ?1.71-point mean
EDSS score change; 16% had stable or improved
EDSS scores. Patients with neither CDI nor
CDW had a -0.10-point mean EDSS score
change; 98% had stable or improved EDSS
scores.
Conclusion: CDI achievement at any point
during the CARE-MS studies was associated with
improved disability at year 9, highlighting the
potential of alemtuzumab to change the mul-
tiple sclerosis course. Conversely, CDW at any
point was associated with worsened disability at
year 9.
Keywords: Alemtuzumab; Confirmed disability
improvement; Confirmed disability worsening;
Disease-modifying therapy; Expanded Disability
Status Scale; Functional systems; Multiple
sclerosis
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Key Summary Points
Why carry out this study?
Neurologic disability accumulates in
patients with relapsing–remitting
multiple sclerosis (RRMS) and has a
negative impact on their lives, but the
correlation between sustained, clinically
meaningful disability improvement
during RRMS treatment and long-term
outcomes is often not fully appreciated.
The CARE-MS studies, which have accrued
9 years of experience with alemtuzumab
in treatment-naive and previously treated
patients with RRMS, provide data that
inform the relationship between
confirmed disability improvement (CDI)
and confirmed disability worsening
(CDW) at any time over the 9 years with
long-term disability outcomes.
What was learned from the study?
Patients with Expanded Disability Status
Scale (EDSS) score C 2.0 at baseline and
who had achieved 6-month CDI at any
point in the CARE-MS studies showed
improved disability outcomes through
year 9, and patients with 6-month CDW
at any time experienced increased
disability through the 9-year follow-up
period.
Of the patients who achieved 6-month
CDI, a substantial majority had
improvements or stabilization in multiple
functional systems (FS) of the EDSS,
including the pyramidal, cerebellar, and
sensory FS, which affect proprioception,
mobility, and coordination, and are
highly relevant to patient functioning.
The robust and sustained improvements
in disability outcomes in patients who
achieved 6-month CDI suggest disability
can be reduced in patients with higher
baseline EDSS scores and indicate a broad,
clinically meaningful treatment effect
with alemtuzumab.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14710542.
INTRODUCTION
Accumulation of neurologic disability nega-
tively impacts the lives of people with multiple
sclerosis (MS) [1, 2]. Preventing disability pro-
gression and, more importantly, improving
preexisting disability over the long term remain
important treatment goals. It is well established
that initiating disease-modifying therapy
(DMT) earlier rather than later in the disease
course delays disability progression [3–5]; how-
ever, it is not always appreciated how disability
improvement or worsening over a defined per-
iod (e.g., 6 months) contributes to long-term
outcomes.
Alemtuzumab (Lemtrada, Sanofi Genzyme,
Cambridge, MA, USA) showed superior efficacy
on relapse and magnetic resonance imaging
(MRI) outcomes versus subcutaneous interferon
beta-1a (SC IFNB-1a; Rebif, EMD Serono, Inc.,
Rockland, MA) over 2 years in the Comparison
of Alemtuzumab and Rebif Efficacy in Multiple
Sclerosis (CARE-MS) studies in patients with
relapsing-remitting MS (RRMS) [6, 7]. In addi-
tion, a significantly greater percentage of alem-
tuzumab-treated patients in CARE-MS II who
had received prior DMT were free of 6-month
confirmed disability worsening (CDW) and
achieved 6-month confirmed disability
improvement (CDI) versus SC IFNB-1a [7, 8].
Alemtuzumab maintained its clinical efficacy
over an additional 7 years in two consecutive
extension studies, the CARE-MS extension
[9, 10] and the ongoing TOPAZ extension study
[11–13]. The underlying mechanism for these
improvements in disability is not fully under-
stood, but could be due to structural and func-
tional repair within the central nervous system
[8, 14].
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CDI has been used as an outcome measure in
DMT trials to assess reversal of patients’ preex-
isting disability [7–10, 15–19]. By requiring a
confirmation of Expanded Disability Status
Scale (EDSS) score change over 6 months, CDI
reflects a sustained and clinically meaningful
improvement in patient functioning, rather
than simple recovery from relapse.
We report an analysis of the pooled CARE-
MS population that evaluated disability status
in alemtuzumab-treated patients who had
6-month CDI, 6-month CDW, or neither CDI
nor CDW over 9 years, and characterized
improvement in individual functional systems
(FS) scores of the EDSS over 6 years.
METHODS
This pooled analysis included patients from
CARE-MS I and II randomized to receive two
courses of alemtuzumab 12 mg/day (5 days at
baseline; 3 days at 12 months), with additional
as-needed 3-day courses in the extensions.
Patients were stratified into three subgroups:
with CDI, with CDW, and with neither CDI nor
CDW. Any patient who experienced both CDI
and CDW during the 9-year period was counted
in both the subgroup of patients with CDI and
the subgroup of patients with CDW. EDSS and
FS scores, as well as annualized relapse rate
(ARR) and quality-of-life (QoL) outcomes, were
assessed. Safety events were recorded through
year 9.
Study Design
This post hoc analysis included only those
patients receiving alemtuzumab 12 mg in the
2-year core CARE-MS I and II trials. Patients who
completed the 2-year core trials could enroll in
the two consecutive extension studies: the
4-year CARE-MS extension study
(CAMMS03409) and the ongoing TOPAZ
extension study. Data are currently available for
a total of 9 years for patients treated with
alemtuzumab. Results from CARE-MS I and II
were pooled for analysis.
Details on the rater-blinded, active-con-
trolled CARE-MS trials and subsequent
extension studies have been published previ-
ously [6, 7, 9–13]. After C 30 days of clinical
stability, patients were randomized to receive
either two courses of alemtuzumab 12 mg/day
(given as intravenous [IV] infusions on 5 con-
secutive days at baseline and on 3 consecutive
days 12 months later) or SC IFNB-1a 44 lg three
times per week after dose titration. Patients in
both groups received IV methylprednisolone
1 g/day on three consecutive days at baseline
and at month 12 [6, 7]. Alemtuzumab-treated
patients who entered the 4-year CARE-MS
extension study could receive additional cour-
ses of alemtuzumab (12 mg/day on 3 consecu-
tive days C 12 months after the most recent
dose) as needed for clinical or magnetic reso-
nance imaging (MRI) disease activity or receive
other licensed DMTs at the investigator’s dis-
cretion [9, 10]. Follow-up of patients beyond
6 years is continuing in the TOPAZ extension
study in which patients can receive additional
alemtuzumab courses (12 mg/day on 3 consec-
utive days C 12 months after the most recent
course) or other DMTs at any time point, both
at the investigator’s discretion (no criteria)
[11–13].
Compliance with Ethics Guidelines
The CARE-MS I and II studies, the CARE-MS
extension, and the TOPAZ extension were reg-
istered with ClinicalTrials.gov (NCT00530348,
NCT00548405, NCT00930553, and
NCT02255656, respectively). The studies were
conducted in accordance with the ethical prin-
ciples outlined in the Declaration of Helsinki.
The study protocol, informed consent forms,
and other study-related documents were
reviewed and approved by the local indepen-
dent ethics committees and institutional review
boards. Written informed consent to participate
in the studies was obtained from all patients.
6-Month CDI and CDW Assessments Over
9 Years
This study evaluated pooled CARE-MS I and II
alemtuzumab-treated patients over 9 years, and
the analysis population for 6-month CDI,
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6-month CDW, or neither 6-month CDI nor
6-month CDW consisted of patients with base-
line EDSS scores C 2.0. Although the entire
study population was eligible for CDW analysis,
a smaller cohort of patients with EDSS score
C 2.0 was analyzed for CDW to ensure consis-
tency of population with those eligible for CDI.
CDI and CDW were defined as a C 1.0-point
decrease and increase, respectively, in EDSS
score from core study baseline confirmed over
6 months. This stringent definition ensured
that only those patients with an improvement
or worsening of preexisting disability at core
study baseline would be classified as having CDI
or CDW, respectively. Mean EDSS scores were
assessed quarterly from core study baseline
through year 6 (end of the CARE-MS extension)
and every 6 months over years 7–9 (TOPAZ).
Improved and stable EDSS scores were defined
as a C 1.0-point decrease and a B 0.5-point
change in either direction, respectively, from
core study baseline at a single time point (i.e.,
did not require confirmation over time) and
were assessed annually over 9 years; results at
year 9 are reported here. To assess the impact of
baseline EDSS score on CDI and CDW, all
patients with 6-month CDI, CDW, or neither
CDI nor CDW were stratified by core study
baseline EDSS scores of 2.0–2.5, 3.0–3.5, 4.0–4.5,
5.0–5.5, and 6.0–6.5.
FS Assessments Over 6 Years
Individual FS scores were assessed at core study
baseline and quarterly through year 6 by raters
blinded to treatment. FS scores were collected
until the end of the CARE-MS extension study,
but not documented as part of the ongoing
TOPAZ study. The FS scores were rated on an
ordinal scale: cerebellar, cerebral, and brainstem
(range 0–5); pyramidal, sensory, bowel/bladder,
and visual (range 0–6) [20]. Improvement in FS
scores was defined as a C 1.0-point decrease
from core study baseline; worsening was
defined as a C 1.0-point increase. Stability in FS
scores was defined as a 0-point change from
core study baseline. Improvement, worsening,
or stability in FS scores since core study baseline
was assessed annually over 6 years; this manu-
script reports results at year 6.
QoL Assessments Over 9 Years
QoL outcomes for alemtuzumab-treated
patients, followed from CARE-MS core study
baseline through completion of year 9, were
collected and stratified by 6-month CDI, CDW,
or neither CDI nor CDW. Four outcome mea-
sures were assessed. The Short Form-36 (SF-36)
mental component summary (MCS) and physi-
cal component summary (PCS) are validated
generic self-assessment questionnaires that
capture patients’ perceptions of their mental
and physical health, respectively, and how they
affect their QoL [21]. Norm-based scores are
utilized for both the MCS and PCS, calibrating
each scale to have a mean of 50 and SD of 10 in
the general US population [22]. The SF-36 was
administered at baseline, every 12 months dur-
ing the core study, every 6 months during year
1 of the extension period, and every 12 months
thereafter [23]. The EuroQol-5 Dimension visual
analog scale (EQ-5D VAS) is a validated, stan-
dardized, self-assessed generic measure of cur-
rent health status that is scored on a visual
analog scale ranging from 0 (worst imaginable
health state) to 100 (best imaginable health
state) [24]. The EQ-5D VAS was administered at
baseline, every 6 months during the core study
and year 1 of the extension period, and every
12 months thereafter [23]. The Functional
Assessment of Multiple Sclerosis (FAMS) is a
validated, MS-specific, patient-reported health-
related QoL questionnaire with 44 scored items
comprising six scales (mobility, symptoms,
emotional well-being, general contentment,
thinking/fatigue, family/social well-being); total
scores range from 0 to 176, with higher scores
indicating better functioning [25]. The FAMS
was administered at baseline, every 6 months
during the core study and year 1 of the exten-
sion period, and every 12 months thereafter
[23]. Worsening and improvement in QoL out-
comes were defined as C 5-point decrease and
C 5-point increase, respectively, from core




This analysis was based on all available data
(without imputation) from all patients who
received alemtuzumab 12 mg in the pooled
CARE-MS studies for up to 9 years of follow-up.
Patients who received SC IFNB-1a in the core
CARE-MS studies and switched to alemtuzumab
in the extension study were not included since
they were unlikely to provide additional insight
into the effects of CDI and CDW on long-term
outcomes, as sufficient alemtuzumab-only
patients were available. No formal statistical
testing was conducted to compare the various
subgroups.
RESULTS
Patients and Disability Events Over 9 Years
In the pooled analysis of 811 alemtuzumab-
treated patients from the CARE-MS I and II
studies, 511 patients (63%) had baseline EDSS
scores C 2 and were included in this analysis
(Fig. 1). The baseline demographic and disease
characteristics observed across subgroups of
patients who experienced CDI, CDW, or neither
CDI nor CDW at any time during the 9-year
period are shown in Table 1. Most patients were
in their fourth decade at study entry, and the
population was predominantly female. Differ-
ences in baseline characteristics between the
cohorts of patients with CDI and CDW included
duration of disease and number of gadolinium
(Gd)-enhancing lesions at baseline. The mean
(SD) time since first symptoms for patients with
CDW was 4.0 (2.8) years, compared with 3.6
(2.5) years for patients with CDI, and 3.4 (2.4)
years for patients with neither CDI nor CDW.
Patients with CDW also had fewer Gd-enhanc-
ing lesions at baseline (mean 2.0, SD 4.3) com-
pared with those with CDI (mean 2.6, SD 6.9) or
neither CDI nor CDW (mean 3.2, SD 7.6)
(Table 1).
Over 9 years, 222/511 patients (43%)
achieved 6-month CDI with a total of 365
events (mean duration 27.2 months), 172/511
patients (34%) experienced 6-month CDW with
a total of 217 events (mean duration
31.3 months), and 148/511 patients (29%) had
neither CDI nor CDW (Fig. 1 and
Fig. 1 Disposition of pooled CARE-MS I and II patients
stratified by 6-month CDI, 6-month CDW, or neither
CDI nor CDW over 9 years. CDI and CDW were defined
as a C 1.0-point decrease and a C 1.0-point increase,
respectively, in EDSS score from core study baseline
confirmed over 6 months, and were assessed only in
patients with EDSS score C 2.0 at core study baseline.
Patients who experienced both CDI and CDW events
during the 9-year period were counted in both groups.
CDI confirmed disability improvement, CDW confirmed
disability worsening, EDSS Expanded Disability Status
Scale
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Supplementary Material). The proportions of
patients in each category exceeded 100%
because 31/511 patients (6%) had both CDI and
CDW events during the 9-year period and were
counted in both groups. For the 222 patients
who achieved 6-month CDI, 65% had an event
during the first 2 years (Supplementary Mate-
rial). Of the 31 patients who had both CDI and
CDW events, 26 had CDW after CDI (i.e., 11.7%
[26/222] of patients who achieved CDI subse-
quently had a CDW), and 5 achieved CDI after
CDW (i.e., 2.9% [5/172] of patients who had a
CDW subsequently had a CDI). The proportion
of patients who received additional alem-
tuzumab courses was lower for those with CDI
(101 patients [45.5%]; comprising 57 [25.7%],
29 [13.1%], 11 [5.0%], 3 [1.4%], and 1 [0.5%]
who received 1, 2, 3, 4, or 5 additional courses,
respectively) than for those with CDW (111
patients [64.5%]; comprising 55 [32.0%], 33
[19.2%], 15 [8.7%], 7 [4.1%], and 1 [0.6%] who
received 1, 2, 3, 4, or 5 additional courses,
respectively; Fig. 1). A higher proportion of
patients with CDI than with CDW remained on
study through year 9 (83% vs. 72%; Fig. 1).
Among both the subgroup with CDI and the
Table 1 Baseline characteristics of patients with 6-month CDI, 6-month CDW, or neither CDI nor CDW over 9 years
Baseline characteristic Patients with 6-month
CDI (n = 222)
Patients with 6-month
CDW (n = 172)
Patients with neither CDI nor
CDW (n = 148)
Age, years 34.5 (8.1) 36.5 (8.1) 33.3 (7.9)
Female, n (%) 150 (68) 114 (66) 93 (63)
Time since first symptoms, years 3.6 (2.5) 4.0 (2.8) 3.4 (2.4)
Relapses in previous year 1.7 (0.9) 1.7 (0.8) 1.7 (0.8)
Relapses in previous 2 years 2.6 (1.0) 2.6 (1.0) 2.7 (1.2)
EDSS score 3.0 (0.8) 3.1 (1.0) 2.7 (0.7)
Number of Gd-enhancing
lesions
2.6 (6.9)a 2.0 (4.3)b 3.2 (7.6)c
Patients with baseline Gd-
enhancing lesions, n (%)
100 (46)a 71 (42)b 59 (40)c
T2 hyperintense lesion volume,
cm3
9.8 (13.0)d 10.9 (13.5)e 9.9 (10.6)c
Brain parenchymal fraction 0.82 (0.02)f 0.81 (0.03)g 0.82 (0.02)h
Values are mean (SD) except where noted. CDI and CDW were defined as a C 1.0-point decrease and a C 1.0-point
increase, respectively, in EDSS score from core study baseline confirmed over 6 months, and were assessed only in patients
with EDSS score C 2.0 at core study baseline
CDI confirmed disability improvement, CDW confirmed disability worsening, EDSS Expanded Disability Status Scale, Gd
gadolinium
a n = 218
b n = 170
c n = 147
d n = 220
e n = 171
f n = 217
g n = 169
h n = 146
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Fig. 2 EDSS scores over 9 years in patients stratified by
a 6-month CDI, b 6-month CDW, or c neither CDI nor
CDW. Line charts represent EDSS scores through 9 years
and bar charts represent improvement or stability in EDSS
scores at year 9 relative to core study baseline, both in
pooled CARE-MS I and II patients who had 6-month
CDI, 6-month CDW, or neither CDI nor CDW at any
time during the 9-year study. CDI and CDW were defined
as a C 1.0-point decrease and a C 1.0-point increase,
respectively, in EDSS score from core study baseline
confirmed over 6 months, and were assessed only in
patients with EDSS score C 2.0 at core study baseline.
Improved and stable EDSS scores were defined as C 1-
point decrease and B 0.5-point change in either direction,
respectively, from core study baseline at a single time point
(year 9), and did not require confirmation over time. CDI
confirmed disability improvement, CDW confirmed dis-
ability worsening, EDSS Expanded Disability Status Scale
Neurol Ther
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subgroup with CDW, patients were most likely
to have had a baseline EDSS score of either
2.0–2.5 (36% of the CDI group; 42% of the
CDW group) or 3.0–3.5 (44% of the CDI group;
36% of the CDW group) (Supplementary
Material).
EDSS Scores in Patients Stratified by CDI
or CDW Status
Patients who achieved CDI at any time on study
had a mean EDSS score change of –0.58 at year 9
versus core study baseline (Fig. 2a). Overall, 88%
of patients achieving CDI had EDSS scores that
remained stable or improved at year 9 relative to
baseline (Fig. 2a). Disability improvements were
also assessed in patients with a pre-CDI EDSS
score above or below 4.0, a threshold associated
with moderate to severe MS. Before the onset of
CDI, 85% of patients had EDSS scores\ 4.0,
which increased to 97% 6 months after achiev-
ing CDI, indicating an improvement in dis-
ability at this EDSS milestone. Acknowledging
the lower retention rate for patients with CDW
than for patients with CDI, the CDW group
experienced worsened disability at year 9 com-
pared with the CDI group, with a ?1.71 mean
change in EDSS score from core study baseline,
and 16% had stable or improved EDSS scores at
year 9 relative to baseline (Fig. 2b). EDSS scores
remained stable at year 9 relative to baseline in
96% of patients who had neither CDI nor CDW,
and an additional 2% of patients had improved
EDSS scores. This subgroup had a –0.10 mean
change in EDSS score from core study baseline
(Fig. 2c).
FS Scores in Patients Stratified by CDI
or CDW Status
Among patients with CDI, confirmed improve-
ments occurred across all FS reported through
the end of the CARE-MS extension study (year
6), with the most frequent improvements
occurring in the cardinal FS domains of pyra-
midal (47%), sensory (40%), and cerebellar
(49%). Overall, 29–33% of patients with CDI
showed improvements in the brainstem, cere-
bral, visual, and bowel/bladder FS (Fig. 3a).
Rates of improvement in 1, 2, 3, and C 4 FS
were 23%, 23%, 24%, and 24%, respectively
(Supplementary Material). Compared with
patients with CDI, lower percentages of patients
with CDW had improved or stable scores across
all FS, with the lowest rate of improvement
observed in the pyramidal FS (11%) (Fig. 3b). A
total of 34% of patients with CDW showed no
improvements in any FS, compared with 6% of
patients with CDI, and 3–11% of patients with
CDW showed improvements in C 3 FS, com-
pared with 24% of those with CDI (Supple-
mentary Material). Among patients with neither
CDI nor CDW, 57–76% had stable FS scores at
year 6 relative to core study baseline (Fig. 3c).
Improvements were observed in multiple FS in
this subgroup of patients, with 37%, 20%, 14%,
and 3% showing improvements in 1, 2, 3,
and C 4 FS, respectively (Supplementary
Material).
ARR in Patients Stratified by CDI or CDW
Status
Cumulatively over years 0–9, ARR (95% CI) was
0.159 (0.133, 0.190), 0.308 (0.270, 0.351), and
0.167 (0.135, 0.207) in patients with CDI,
patients with CDW, and patients with neither
bFig. 3 FS scores over 6 years in patients stratified by a 6-
month CDI, b 6-month CDW, or c neither CDI nor
CDW. Includes pooled CARE-MS I and II patients who
had 6-month CDI, 6-month CDW, or neither CDI nor
CDW at any time during the 9-year study. CDI and
CDW were defined as a C 1.0-point decrease and
a C 1.0-point increase, respectively, in EDSS score from
core study baseline confirmed over 6 months, and were
assessed only in patients with EDSS score C 2.0 at core
study baseline. FS scores were collected through the end of
the CARE-MS extension (year 6), and were not recorded
in the TOPAZ extension (years 7–9). Improved and
stable FS scores were defined as C 1-point decrease
and B 1-point change in either direction, respectively,
from core study baseline at a single time point (year 6), and
did not require confirmation over time. Sum of percent-
ages with improved and stable FS scores may differ due to
rounding. CDI confirmed disability improvement, CDW
confirmed disability worsening, EDSS Expanded Disability
Status Scale, FS functional systems
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CDI nor CDW, respectively (Supplementary
Material). During each year from year 1 to year
9, the ARR was consistently higher in patients
with CDW compared with the other two patient
subgroups (Supplementary Material).
QoL Scores in Patients Stratified by CDI
or CDW Status
Over 9 years, 34% and 37% of patients with CDI
had improvements on the SF-36 MCS and PCS,
respectively. Rates of improvements were 49%
on the EQ-5D VAS and 56% on the FAMS
(Supplementary Material). Lower proportions of
patients with CDW had improved QoL scores
across all assessments (SF-36 MCS, 31%; SF-36
PCS, 14%; EQ-5D VAS, 33%; FAMS, 28%) over
9 years (Supplementary Material). Similarly,
lower proportions of patients with neither CDI
nor CDW showed improvements across QoL
assessments compared with those with CDI,
with the exception of SF-36 MCS (Supplemen-
tary Material).
Safety
Rates of adverse events (AEs), including infec-
tions and autoimmune AEs, were similar for
patients with 6-month CDI, 6-month CDW, or
neither CDI nor CDW (Supplementary Mate-
rial). Overall, thyroid AEs were more common
in the CDI group (55%) than in the CDW (49%)
or neither CDI nor CDW group (41%), but rates
of serious thyroid AEs were similar for the three
groups. Compared with those who achieved
CDI, patients with CDW had an apparent
increased incidence of serious AEs (54% vs.
45%) and deaths (4% vs. 2%). Malignancy rates
remained low across all subgroups (1–2%).
DISCUSSION
For treatment-refractory patients with MS,
decisions on subsequent therapy are driven in
the first instance by the goals of stabilizing
disability levels and preventing further wors-
ening of disability. A further target is improve-
ment of patients’ disability status, and the
findings from our study support the robustness
of the relatively novel outcome parameter CDI.
However, substantial variability in disease
course within and among patients complicates
disability assessments. Moreover, biases in
patient retention complicate interpretation of
long-term disability outcomes beyond the typ-
ical 1–3 years of follow-up in randomized trial
assessments [26]. Previous studies that have
conceptualized the natural history of MS as a
two-phase disease have suggested that patients
with advanced disease (i.e., EDSS score C 4.0)
do not benefit from therapeutic intervention
because their disease is mainly neurodegenera-
tive and independent of inflammation [27, 28].
The contemporary view of MS disease trajec-
tory, however, suggests that disability accumu-
lation is driven by relapses (i.e., inflammatory
events) and brain atrophy at any time in the
disease course, leading to highly variable treat-
ment outcomes in patients with advanced dis-
ease [29–31]. Sustained improvements in
preexisting disability with alemtuzumab, even
among patients with higher baseline EDSS
scores, are consistent with this view and
emphasize the importance of continuing highly
effective treatment in advanced MS. The non-
linearity of the EDSS rating makes it insensitive
to measurements other than gait disturbances
in patients with scores C 4.0 [32]. Hence, in
these patients, FS score improvements may have
a greater clinical impact than numerical
improvements in EDSS scores. Interestingly, the
rates of CDI in the post hoc analysis reported
here were 44% in patients with baseline EDSS
scores of 3.0–3.5 compared with 36% for
patients with baseline EDSS scores of 2.0–2.5,
and 69% of the former had improvement or
stability in C 2 FS (data not shown). Although
the underlying mechanism of improving pre-
existing disability based on EDSS is unclear,
studies have shown a proportional association
between the magnitude of ongoing inflamma-
tory activity and axonal injury (i.e., neurode-
generation) in all disease stages of MS [33].
Most importantly, 88% of alemtuzumab
patients who achieved 6-month CDI continued
to show improved (51%) or stable (37%) EDSS
scores at year 9 compared with study baseline.
This is in contrast to patients with CDW, of
Neurol Ther
whom 16% had improved (2%) or stable (14%)
EDSS scores at year 9. The majority of patients
(96%) with neither CDI nor CDW had
stable EDSS scores; 2% had improved EDSS
scores at year 9.
The burden of Gd-enhancing lesions at
baseline was greater for patients with CDI or
with neither CDI nor CDW compared with
patients with CDW. This could suggest that
patients with lower inflammatory activity (as
measured by fewer Gd-enhancing lesions) have
a more advanced disease course and may have
poorer outcomes than patients presenting with
earlier stages of RRMS, and supports the ratio-
nale for the treatment of early MS with alem-
tuzumab [34]. Alternatively, these findings
could also suggest that patients with advanced
focal inflammatory disease may be better
responders to a highly effective treatment, such
as alemtuzumab. To this end, previous studies
have suggested that long-term disability
improvements with alemtuzumab may not be
solely due to its anti-inflammatory effect, but
may be also attributable to a neuroprotective
effect via neurotrophin secretion from immune
cells regenerating after alemtuzumab treatment
[35].
The FS of the EDSS play a key role in defining
disease progression in patients with MS [36]. In
a typical cohort of patients with MS, the pyra-
midal, cerebellar, and sensory FS tended to be
most affected at baseline, yet were also the most
likely FS to improve in response to treatment
[36, 37]. Of the alemtuzumab-treated patients
who achieved 6-month CDI, 72% showed
improvements in C 2 FS, including in the
pyramidal (47%), cerebellar (49%), and sensory
(40%) FS. These findings are consistent with
previous observations from the phase 2
CAMMS223 trial, showing greatest improve-
ments with alemtuzumab versus SC IFNB-1a for
pyramidal, cerebellar, and sensory FS [38]. These
FS affect proprioception, mobility, and coordi-
nation, and are highly relevant to patient
functioning. Given the negative impact of
functional and mobility impairments on the
QoL of patients with MS [2], these robust and
sustained improvements in each FS suggest that
dysfunction can be repaired in patients with
higher baseline EDSS scores, and indicate a
broad and clinically meaningful treatment
effect with alemtuzumab.
In this analysis, QoL endpoints mirrored
long-term disability outcomes, with higher
percentages of patients with 6-month CDI ver-
sus 6-month CDW achieving improvements in
SF-36 MCS, SF-36 PCS, EQ-5D VAS, and FAMS
scores. Over 9 years of follow-up, the safety
profile of alemtuzumab was generally similar in
patients with CDI, CDW, or neither CDI nor
CDW. Differences were noted, however, in rates
of serious AEs for patients with CDW (54%)
compared with patients with CDI (45%) and
neither CDI nor CDW (38%), which is perhaps
expected given that, by definition, patients with
6-month CDW have poorer outcomes.
The search for prognostic factors that con-
tribute to long-term outcomes in patients with
RRMS remains an active area of ongoing
research. The concept of disability status chan-
ges during treatment is increasingly recognized
as a clinically relevant endpoint in recent
studies [39–41]. One key strength of this anal-
ysis is the large sample size from two random-
ized, active-controlled, rater-blinded, phase 3
studies with a well-defined population of both
treatment-naive and previously treated patients
with RRMS. This analysis also presents data for
both patients with improved disability and
worsened disability. The 83% retention rate of
patients with CDI, 72% of CDW, and 68% of
neither CDI nor CDW through year 9 in the
TOPAZ extension study provides further sup-
port for the robustness of this analysis.
Although improvements in preexisting disabil-
ity have been reported with other DMTs, they
were in placebo-controlled trials using a less
stringent definition of CDI (3-month CDI, 0.5-
point EDSS improvement) and a shorter dura-
tion of follow-up [15–18]. One recently reported
study followed 1882 patients with RRMS for a
median of 1.6 years and found that CDI rates
were 11% for ofatumumab and 8% for teri-
flunomide (hazard ratio 1.35, P = 0.09) [39].
The main limitation of this study is its post
hoc nature, the inter-rater variability in EDSS
and FS score assessments, the widely acknowl-
edged weighting of ambulation in EDSS scoring
and insensitivity to cognitive dysfunction, and
the relatively small sample sizes of the
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subgroups stratified by baseline EDSS score.
Nevertheless, the EDSS is a rigorous and valu-
able tool to capture neurologic disability in
patients, recognized as an important compo-
nent in evaluating comparative DMT efficacy in
MS trials. A further limitation is that the factors
that define the patient subgroups in this study
(presence of CDI or CDW), as well as some of
the outcomes assessed, share EDSS score as a
common source, which precludes the possibil-
ity of statistical comparisons being performed
between the patients with CDI or CDW.
CONCLUSIONS
Achieving continuous and sustained disability
improvements across the FS of the EDSS for
many years after initiation of DMT is an
important treatment goal in MS, as it directly
affects daily functioning. To this end, the EDSS
reflects only the most severely impaired FS
scores, and improvements in multiple less
impaired domains may go unnoticed on the
EDSS in disabled patients. Although long-term
biases in follow-up tend to favor treatment
successes, the long-term retention and
improvements present in even some of the
patients who had experienced instances of
CDW in our study indicate that these findings
reflect meaningful disability improvements
over time. The improvement in multiple aspects
of disability in patients with RRMS over 9 years
highlights the potential for alemtuzumab to
change the MS disease course.
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